IMAB Company Report

Analyst Coverage

Research analysts who have asked questions during IMAB earnings calls.

Andres Maldonado

H.C. Wainwright & Co.

4 questions for IMAB

Also covers: DAWN, SRRK

Kelly Shi

Jefferies

4 questions for IMAB

Also covers: ADCT, AGEN, ALDX +17 more

Louise Chen

Cantor Fitzgerald

3 questions for IMAB

Also covers: AMGN, ARDX, CNTB +16 more

Joe Catanzaro

Piper Sandler

2 questions for IMAB

Also covers: AADI, CNTB, CTMX +1 more

Albert Lowe

Craig-Hallum Capital Group LLC

1 question for IMAB

Also covers: SKYE

Bing Zhao

China Renaissance

1 question for IMAB

Gil Blum

Needham & Company

1 question for IMAB

Also covers: ABSI, AUTL, CELC +9 more

Joseph Catanzaro

Wolfe Research, LLC

1 question for IMAB

Also covers: AADI, CPRX, CRDF +7 more

Qu Xiaoyi

CICC

1 question for IMAB

Yingqi Peng

UBS

1 question for IMAB

Zhuxuan Jiang

CITIC Securities

1 question for IMAB

Latest news

Recent press releases and 8-K filings for IMAB.

NovaBridge Biosciences Files for Hong Kong Dual Listing and Reports Financials

IMAB

Delisting/Listing Issues

Earnings

M&A

NovaBridge Biosciences has applied for a dual primary listing on the Hong Kong Stock Exchange, which is a key element of its global growth strategy to broaden its investor base, enhance trading liquidity, and access capital.
The company reported net losses of US$207.7 million in 2023, US$22.2 million in 2024, and US$8.7 million for the six months ended June 30, 2025. Research and development expenses decreased to US$4,071 thousand for the six months ended June 30, 2025, from US$11,265 thousand for the same period in 2024, primarily due to decreased headcount and reimbursements following a strategic reprioritization.
As part of a strategic shift to become a U.S.-based global biotechnology platform company, NovaBridge Biosciences divested its Greater China assets and business operations on April 2, 2024, for an aggregate consideration of up to US$80 million contingent on milestones.
The company's core product, givastomig, a novel bispecific antibody for various cancers, is expected to initiate a randomized Phase 2 study in early 2026.

Oct 31, 2025, 10:04 AM

6-K

NovaBridge Subsidiary Visara Assigns VIS-101 License to Everest Medicines; Appoints Ian Woo to Board

IMAB

New Projects/Investments

Board Change

NovaBridge Biosciences' subsidiary, Visara, assigned its exclusive license for VIS-101 to Everest Medicines for development, manufacture, and commercialization in Greater China, Singapore, South Korea, and certain other Asian countries on October 28, 2025. Everest Medicines will assume all payment obligations under the assigned license agreement and reimburse Visara for any upfront payments already made.
NovaBridge Biosciences also appointed Mr. Ian Ying Woo as an independent member of its Board of Directors, effective October 15, 2025. Mr. Woo is currently the President, Chief Financial Officer, and Director of Everest Medicines Limited.
VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, which is completing a Phase 2 study in China and is anticipated to be Phase 3-ready in 2026.

Oct 29, 2025, 11:00 PM

6-K

I-Mab Transitions to NovaBridge Biosciences with New Ticker NBP

IMAB

Delisting/Listing Issues

New Projects/Investments

I-Mab has officially changed its corporate name to NovaBridge Biosciences.
Effective October 30, 2025, the company's American Depositary Shares (ADSs) will commence trading on Nasdaq under the new ticker symbol "NBP", replacing "IMAB".
The name change, approved by shareholders on October 24, 2025, reflects a strategic transformation to a global biotech platform, which includes plans for a Hong Kong initial public offering (IPO) and dual listings on Nasdaq and HKEX.
No action is required from current shareholders, and the CUSIP number for the ADSs remains unchanged.

Oct 29, 2025, 8:05 PM

6-K

I-Mab Completes Acquisition of Bridge Health Biotech

IMAB

M&A

New Projects/Investments

I-Mab's wholly owned subsidiary, I-Mab Biopharma Hong Kong Limited, closed the acquisition of Bridge Health Biotech Co., Ltd. on October 28, 2025.
The transaction included an upfront payment of $1.8 million and non-contingent payments of $1.2 million through 2027.
Bridge Health shareholders are eligible for future milestone payments of up to $3.875 million, contingent on the achievement of certain development and regulatory milestones.
This acquisition provides I-Mab with rights to bispecific and multi-specific applications, including antibodies and antibody drug conjugates (ADCs), based on the Claudin 18.2 (CLDN18.2) parental antibody.

Oct 28, 2025, 8:01 PM

6-K

I-Mab Reports Updated Phase 1 Monotherapy Results for Givastomig in Gastroesophageal Carcinoma

IMAB

New Projects/Investments

I-Mab released updated Phase 1 monotherapy study results for Givastomig, a novel bispecific antibody, in CLDN18.2-positive advanced Gastroesophageal Carcinoma (GEC).
The study, with data cut-off on August 27, 2025, showed Givastomig was well tolerated, with no dose-limiting toxicities observed up to 15mg/kg Q2W and 18 mg/kg Q3W, and the maximum-tolerated-dose was not reached.
In 45 heavily pre-treated GEC patients, Givastomig demonstrated a confirmed Overall Response Rate (ORR) of 18% and a Disease Control Rate (DCR) of 48.9%.
The results indicate potential utility for Givastomig in patients with lower CLDN18.2 expression, as no statistically significant differences in efficacy were observed between CLDN18.2-high and CLDN18.2-low groups.
These findings support the continued development of Givastomig, including its evaluation as an add-on to first-line therapy.

Oct 24, 2025, 4:35 PM

6-K

I-Mab to Present Positive Givastomig Monotherapy Data and Announces Name Change

IMAB

New Projects/Investments

I-Mab will present positive updated Phase 1 givastomig monotherapy data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025.
The updated data from 45 heavily pre-treated metastatic gastric cancer patients show an 18% Objective Response Rate (ORR), with responses observed across various dose ranges and CLDN18.2 expression levels, alongside favorable overall safety.
These results support a combination clinical strategy for givastomig in first-line gastric cancer, a $2 billion potential market.
The company expects to report topline Phase 1b dose expansion combination data and initiate a global randomized Phase 2 study in Q1 2026.
I-Mab also announced its intention to change its name to NovaBridge Bioscience, pending Extraordinary General Meeting (EGM) approval on October 24, 2025.

Oct 22, 2025, 4:38 PM

6-K

I-Mab Unveils Nova Bridge Business Transformation and Key Acquisition

IMAB

New Projects/Investments

M&A

I-Mab is undergoing a business transformation, evolving into Nova Bridge, a global biotech platform focused on bridging Asian innovation to global markets by leveraging discovery capabilities in China and clinical development in the U.S..
The core strategy involves in-licensing clinical-stage assets, developing them to proof of concept (POC) within two to three years, and then potentially out-licensing, spinning off, or continuing late-phase development.
As part of this strategy, I-Mab acquired VIS 101, a bifunctional biologic for wet AMD and DME, for $37 million for a controlling share of global rights, marking its entry into ophthalmology through a new subsidiary, Vice Sara.
The phase two trial for VIS 101 is expected to read out top-line results by the end of 2025 or Q1 2026, with global phase three studies anticipated to begin in 2026.

Oct 16, 2025, 8:45 PM

Transcript

I-Mab announces strategic transformation to NovoBridge and new platform business model

IMAB

New Projects/Investments

Management Change

M&A

I-Mab is undergoing a strategic transformation, rebranding to NovoBridge, and evolving into a global biotech platform with operations in China and the US.
The new business model will focus on in-licensing clinical-stage assets, developing them to proof-of-concept (POC) within 2-3 years, and then pursuing various exit strategies such as out-licensing or spin-offs.
As part of this strategy, NovoBridge acquired global rights to VS-101, a bifunctional biologic for wet AMD and DME, for $37 million through a new subsidiary, Viscera.
Buwei, founder and CEO of CBC Group, which manages over $10 billion, has been appointed Executive Chairman of I-Mab (NovoBridge), bringing extensive investment and deal execution experience.
The company confirmed its commitment to advancing existing clinical-stage assets, including GivaStomig, alongside the new platform strategy.

Oct 16, 2025, 8:45 PM

Transcript

I-Mab Announces Strategic Transformation, Hong Kong IPO Intent, Rebranding, and CFO Appointment

IMAB

New Projects/Investments

CFO Change

M&A

I-Mab announced a strategic transformation to a global biotech platform and its intention to rebrand as NovaBridge Biosciences, pending shareholder approval at an Extraordinary General Meeting on October 24, 2025.
The company intends to pursue a Hong Kong initial public offering (IPO) to achieve a dual listing on NASDAQ and the Hong Kong Stock Exchange (HKEX).
A newly formed subsidiary, Visara, Inc., will acquire VIS-101, a novel bifunctional biologic, with I-Mab investing approximately $37 million in Visara's Series A preferred stock.
Mr. Kyler Lei has been appointed as the new Chief Financial Officer, effective October 16, 2025, replacing Mr. Joseph Skelton.

Oct 16, 2025, 8:05 PM

6-K

I-Mab Reports First Half 2025 Results, Underwritten Offering, and Strategic Acquisition

IMAB

Earnings

M&A

New Projects/Investments

I-Mab reported a net loss of $8.654 million for the six months ended June 30, 2025, compared to a net income of $9.106 million for the same period in 2024, with research and development expenses decreasing by 63.9% to $4.1 million.
The company completed an underwritten offering on August 5, 2025, raising approximately $61.2 million in net proceeds from the issuance of 33,333,330 American depositary shares (ADSs) at $1.95 per ADS.
As of June 30, 2025, cash and cash equivalents increased significantly to $165.404 million, up from $68.263 million as of December 31, 2024.
I-Mab expects to acquire Bridge Health Biotech Co., Ltd early in the fourth quarter of 2025 for an upfront payment of $1.8 million and potential milestone payments, gaining rights to bispecific and multi-specific applications based on the Claudin 18.2 parental antibody.
The divestiture of its Greater China assets and business operations was completed on April 2, 2024, for an aggregate consideration of up to $80 million contingent on future milestones and royalties.